SynKinase

Danusertib

As low as CHF 0.00
In stock
Only %1 left
SYN-1095-M0011 mgCHF 149.00
SYN-1095-M0055 mgCHF 241.00
SYN-1095-M01010 mgCHF 440.00
SYN-1095-M05050 mgCHF 1’348.00
SYN-1095-M100100 mgINQ

Specifications / Handling

More Information
Product Details
Synonyms PHA-739358
Product Type Chemical
Properties
Formula

C26H30N6O3

MW 474.6
CAS 827318-97-8
Purity Chemicals ≥95%
Appearance Solid.
Solubility Soluble in DMSO or ethanol.
Declaration Manufactured by SynKinase.
Other Product Data

Target: Abl - Aurora A - BCR - FGFR | Kinase Group: Other | Substrate: Serine-Threonine

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

InChi Key XKFTZKGMDDZMJI-HSZRJFAPSA-N
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF Download PDF
Product Specification Sheet
Datasheet Download PDF Download PDF

Scientific Background Information

Product Description

Aurora kinases are key regulators of protein phosphorylation during mitosis, and these serine/threonine kinases interact with other cellular proteins to help control chromosome assembly and segregation during mitosis. Aurora kinases are often highly expressed in malignancies and solid tumors. Danusertib (PHA-739358) is a small molecule pan- Aurora kinase inhibitor that also has activity against other cancer-relevant kinases such as Bcr-Abl tyrosine kinase. Other off target effects of danusertib include inhibition of receptor tyrosine kinases such as FGFR-1, and TrkA. Danusertib demonstrates nanomolar IC(50) values for the Aurora kinases all under 100nM and it also demonstrates potent anti-proliferation effects in cell proliferation assays with IC(50) values ranging from 20nM for A2780 cells to <200nM.

Product-specific References
  1. 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile: D. Fancelli, et al.; J. Med. Chem. 49, 7247 (2006)
  2. Targeting aurora kinases with danusertib (PHA-739358) inhibits growth of liver metastases from gastroenteropancreatic neuroendocrine tumors in an orthotopic xenograft model: K. Fraedrich, et al.; Clin. Cancer Res. 18, 4621 (2012)
  3. Splice Modulation Synergizes Cell Cycle Inhibition: A. Kelsey, et al.; ACS Chem. Biol. ahead of print (2020)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.